Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

ClinicalTrials.gov ID: NCT01365507

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01365507. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily in Insulin-naïve Subjects With Type 2 Diabetes Mellitus When Using Two Different Titration Algorithms (BOOST™: SIMPLE USE)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when using two different titration algorithms (dose individually adjusted) as add-on to subject's ongoing treatment with metformin.

Study identification

NCT ID
NCT01365507
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
276 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2011 (Type not available)
Primary completion
Apr 2012 (Actual)
Completion
Apr 2012 (Actual)
Last update posted
Mar 17, 2017

2011 – 2012

United States locations

U.S. sites
25
U.S. states
11
U.S. cities
23
Facility City State ZIP Site status
Novo Nordisk Investigational Site Concord California 94520-1926 —
Novo Nordisk Investigational Site Los Angeles California 90057 —
Novo Nordisk Investigational Site Montclair California 91763 —
Novo Nordisk Investigational Site Palm Springs California 92262 —
Novo Nordisk Investigational Site Spring Valley California 91978 —
Novo Nordisk Investigational Site Jacksonville Florida 32209-6511 —
Novo Nordisk Investigational Site Jacksonville Florida 32258 —
Novo Nordisk Investigational Site Pembroke Pines Florida 33027 —
Novo Nordisk Investigational Site Crestview Hills Kentucky 41017-3464 —
Novo Nordisk Investigational Site Madisonville Kentucky 42431 —
Novo Nordisk Investigational Site Paducah Kentucky 42003 —
Novo Nordisk Investigational Site Hyattsville Maryland 20782 —
Novo Nordisk Investigational Site North East Maryland 21901 —
Novo Nordisk Investigational Site Detroit Michigan 48235 —
Novo Nordisk Investigational Site Troy Michigan 48085-5524 —
Novo Nordisk Investigational Site Eagan Minnesota 55123 —
Novo Nordisk Investigational Site Smithtown New York 11787 —
Novo Nordisk Investigational Site Asheboro North Carolina 27203 —
Novo Nordisk Investigational Site Dallas Texas 75230 —
Novo Nordisk Investigational Site Dallas Texas 75246 —
Novo Nordisk Investigational Site Houston Texas 77070 —
Novo Nordisk Investigational Site Lubbock Texas 79423 —
Novo Nordisk Investigational Site Sugar Land Texas 77478 —
Novo Nordisk Investigational Site Newport News Virginia 23606 —
Novo Nordisk Investigational Site Milwaukee Wisconsin 53209 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01365507, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 17, 2017 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.